{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:48:27Z","timestamp":1790995707932,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"DOI":"10.7759\/cureus.29140","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T04:32:16Z","timestamp":1663129936000},"source":"Crossref","is-referenced-by-count":12,"title":["A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease"],"prefix":"10.7759","author":[{"given":"Emmanuelar O","family":"Igweonu-Nwakile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safina","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomi","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Yakkali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Teresa Selvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Bikeyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Radivojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas A","family":"Abu Jad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvesh","family":"Ravanavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Balani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Chronic kidney disease in the united states 2021. (2022). Accessed. April 25, 2022: https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8871-2_1","article-title":"Prevalence and disease burden of chronic kidney disease","volume":"1165","author":"Lv JC","year":"2019","unstructured":"Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019, 1165:3-15. 10.1007\/978-981-13-8871-2_1","journal-title":"Adv Exp Med Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey AS","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, et al.. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67:2089-100. 10.1111\/j.1523-1755.2005.00365.x","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/jigims.jigims_6_20","article-title":"Management of dyslipidemia in chronic kidney disease","volume":"7","author":"Singh PP","year":"2021","unstructured":"Singh PP, Krishna A, Kumar O. Management of dyslipidemia in chronic kidney disease. J Indira Gandhi Inst Med Sci. 2021, 7:2-5. 10.4103\/jigims.jigims_6_20","journal-title":"J Indira Gandhi Inst Med Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002506","article-title":"Chronic kidney disease as a cardiovascular risk factor","volume":"38","author":"Carmena R","year":"2020","unstructured":"Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens. 2020, 38:2110-21. 10.1097\/HJH.0000000000002506","journal-title":"J Hypertens"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro CJ","year":"2018","unstructured":"Ferro CJ, Mark PB, Kanbay M, et al.. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018, 14:727-49. 10.1038\/s41581-018-0072-9","journal-title":"Nat Rev Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in\u00a0chronic kidney disease in the FOURIER\u00a0trial","volume":"73","author":"Charytan DM","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, et al.. Efficacy and safety of evolocumab in\u00a0chronic kidney disease in the FOURIER\u00a0trial. J Am Coll Cardiol. 2019, 73:2961-70. 10.1016\/j.jacc.2019.03.513","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S261719","article-title":"Cardiovascular outcomes and proprotein convertase subtilisin\/kexin type 9 inhibitors: current data and future prospects","volume":"16","author":"Duprez DA","year":"2020","unstructured":"Duprez DA, Handelsman Y, Koren M. Cardiovascular outcomes and proprotein convertase subtilisin\/kexin type 9 inhibitors: current data and future prospects. Vasc Health Risk Manag. 2020, 16:403-18. 10.2147\/VHRM.S261719","journal-title":"Vasc Health Risk Manag"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 biology and Its role in atherothrombosis","volume":"22","author":"Barale C","year":"2021","unstructured":"Barale C, Melchionda E, Morotti A, Russo I. PCSK9 biology and Its role in atherothrombosis. Int J Mol Sci. 2021, 22:10.3390\/ijms22115880","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0858-2","article-title":"Lipid management in chronic kidney disease: systematic review of PCSK9 targeting","volume":"78","author":"Zheng-Lin B","year":"2018","unstructured":"Zheng-Lin B, Ortiz A. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs. 2018, 78:215-29. 10.1007\/s40265-017-0858-2","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.789931","article-title":"Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol","volume":"8","author":"Bardolia C","year":"2021","unstructured":"Bardolia C, Amin NS, Turgeon J. Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med. 2021, 8:789931. 10.3389\/fcvm.2021.789931","journal-title":"Front Cardiovasc Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20190029","article-title":"PCSK9 inhibitors: clinical relevance, molecular mechanisms, and safety in clinical practice","volume":"112","author":"Ferrari F","year":"2019","unstructured":"Ferrari F, Stein R, Motta MT, Moriguchi EH. PCSK9 inhibitors: clinical relevance, molecular mechanisms, and safety in clinical practice. Arq Bras Cardiol. 2019, 112:453-60. 10.5935\/abc.20190029","journal-title":"Arq Bras Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth PP","year":"2018","unstructured":"Toth PP, Dwyer JP, Cannon CP, et al.. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018, 93:1397-408. 10.1016\/j.kint.2017.12.011","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.01.001","article-title":"Efficacy and safety of alirocumab in statin-intolerant patients over 3\u00a0years: open-label treatment period of the ODYSSEY ALTERNATIVE trial","volume":"14","author":"Moriarty PM","year":"2020","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al.. Efficacy and safety of alirocumab in statin-intolerant patients over 3\u00a0years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. J Clin Lipidol. 2020, 14:88-97.e2. 10.1016\/j.jacl.2020.01.001","journal-title":"J Clin Lipidol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.05.016","article-title":"Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2\u00a0years","volume":"11","author":"Farnier M","year":"2017","unstructured":"Farnier M, Colhoun HM, Sasiela WJ, Edelberg JM, Asset G, Robinson JG. Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2\u00a0years. J Clin Lipidol. 2017, 11:986-97. 10.1016\/j.jacl.2017.05.016","journal-title":"J Clin Lipidol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter LA","year":"2017","unstructured":"Leiter LA, Cariou B, M\u00fcller-Wieland D, et al.. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017, 19:1781-92. 10.1111\/dom.13114","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2020.04.020","article-title":"Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease","volume":"40","author":"Quiroga B","year":"2020","unstructured":"Quiroga B, Mu\u00f1oz Ramos P, \u00c1lvarez Chiva V. Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease. Nefrologia (Engl Ed). 2020, 40:499-505. 10.1016\/j.nefro.2020.04.020","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00014","article-title":"Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials","volume":"6","author":"Wong ND","year":"2019","unstructured":"Wong ND, Shapiro MD. Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials. Front Cardiovasc Med. 2019, 6:14. 10.3389\/fcvm.2019.00014","journal-title":"Front Cardiovasc Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/101460-a-systematic-review-on-the-safety-and-efficacy-of-pcsk9-inhibitors-in-lowering-cardiovascular-risks-in-patients-with-chronic-kidney-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:28Z","timestamp":1707508048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/101460-a-systematic-review-on-the-safety-and-efficacy-of-pcsk9-inhibitors-in-lowering-cardiovascular-risks-in-patients-with-chronic-kidney-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.29140","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}